How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Direct to Consumer Microbiome Analyzing Market
- By Sample Type: Gut Microbiome, Oral Microbiome, Skin Microbiome, Vaginal Microbiome, Nasal Microbiome
- By Analysis Technology: 16S rRNA Gene Sequencing, Shotgun Metagenomic Sequencing, qPCR-based Microbiome Profiling, Microarray-based Microbiome Analysis
- By Purpose of Testing: Digestive Health Assessment, Immune System Support, Personalized Nutrition Recommendations, Skin Health Optimization, Weight Management
- By Service Model: Subscription-based Testing Kits, One-time Testing Kits, Integrated Health Platform with Microbiome Analysis, Telehealth Consultation with Microbiome Insights
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Gut Microbiome leads By Sample Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 277 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.166 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.174 →
Full report · locked preview
Everything inside the Direct to Consumer Microbiome Analyzing Market report
A complete, evidence-based study - 11 chapters and 116 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Companies profiled
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Viome
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →uBiome (acquired by Psomagen)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →DayTwo
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Thryve Inside
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Atlas Biomed
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Biomesight
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Sun Genomics
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Floré by Sun Genomics
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Microba
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Gut Microbiota Test by Microbiome Labs
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Genova Diagnostics
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →American Gut Project
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Omnibiotics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Pendulum Therapeutics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →BiomeSense
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Gut Microbiome38.4
- Oral Microbiome19.9
- Skin Microbiome11.9
- Vaginal Microbiome10.3
- Nasal Microbiome19.5
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Viome15.6
- uBiome (acquired by Psomagen)23.6
- DayTwo12.2
- Thryve Inside7.8
- Atlas Biomed4.6
- Biomesight8.2
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.9
- Europe23.3
- Asia Pacific20.4
- Latin America13.3
- Middle East and Africa10.1
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Viome | 99 | 98 | 87 | 87 | 80 | 82 | 89 |
| uBiome (acquired by Psomagen) | 86 | 82 | 89 | 89 | 84 | 70 | 83 |
| DayTwo | 84 | 63 | 63 | 84 | 88 | 88 | 78 |
| Thryve Inside | 60 | 70 | 58 | 80 | 77 | 59 | 67 |
| Atlas Biomed | 66 | 61 | 61 | 74 | 70 | 65 | 66 |
| Biomesight | 50 | 50 | 51 | 49 | 54 | 54 | 51 |
| Sun Genomics | 59 | 59 | 45 | 55 | 43 | 53 | 52 |
| Floré by Sun Genomics | 48 | 60 | 57 | 36 | 57 | 43 | 50 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Viome
- uBiome (acquired by Psomagen)
- DayTwo
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Viome | ✓ | ✓ | ✓ | ✓ | ✓ | ◐ |
| uBiome (acquired by Psomagen) | ✓ | ✓ | ◐ | ✓ | ◐ | − |
| DayTwo | ◐ | − | − | ✓ | ✓ | ◐ |
| Thryve Inside | − | ✓ | ◐ | ◐ | ◐ | ◐ |
| Atlas Biomed | − | − | − | ◐ | ✓ | ✓ |
| Biomesight | − | ◐ | − | ◐ | ◐ | ◐ |
| Sun Genomics | − | − | − | ◐ | − | ◐ |
| Floré by Sun Genomics | ◐ | − | ◐ | ◐ | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Challenger1
Strong scale, closing on the leaders.
Contender1
Focused players with pockets of strength.
Niche3
Specialists in a single segment or region.
Go-to-market strategy
Land Sample Type in North America, then scale across Direct to Consumer Microbiome Analyzing Market — a $250M beachhead inside a $3.66B market.
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Gut Microbiome
Best fit — highest urgency & budget in Sample Type.
Oral Microbiome
Strong fit — clear ROI and a fast path to value.
Skin Microbiome
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Sample Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Analysis Technology & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Purpose of Testing
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Positioning & messaging
§GTM 2 · p.194 →For Sample Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Direct to Consumer Microbiome Analyzing Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Investment thesis
Direct to Consumer Microbiome Analyzing Market is a high-growth opportunity — $7.69B by 2033, compounding at 11.6%.
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →11.6% CAGR
Demand compounds through 2033, outpacing GDP across Sample Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Sample Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →Return scenarios (2033 market value)
Fig. 6 · p.22 →Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Analysis Technology optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Direct to Consumer Microbiome Analyzing Market — a $5.44B market by 2033. Plan: grow share from 7.2% to 12.6%.
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.2% | 12.6% | Behind |
| Revenue | $365M | $685M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 35.3% | 39.2% | At risk |
| Customer retention | 85.1% | 95.5% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →Lead segment
Win in Sample Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
Adjacency
Build Analysis Technology capability
A defensible second engine — invest in Analysis Technology to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Sample Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Analysis Technology
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $72M capacity & capability investment
- Greenlight bolt-on M&A in Analysis Technology
- Authorise North America expansion plan
- Fund R&D program for Sample Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentAhead
Sales deck · value proposition
Win the Direct to Consumer Microbiome Analyzing Market conversation — a $7.87B market you can size, segment and defend in minutes.
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Sample Type
Goal Grow share in Sample Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →The business case (ROI)
Fig. 2 · p.9 →Why buyers trust it (proof points)
§1.3 · p.12 →Coverage includes
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Direct to Consumer Microbiome Analyzing Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
Your report is ready to access
Direct to Consumer Microbiome Analyzing Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Direct-to-consumer Genetic Testing Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportDirect-to-consumer Genetic Sequencing Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportDirect-to-consumer Genetic Health Sequencing Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportDirect-To-Consumer (DTC) Genetic Testing Market
Market size, share, segmentation and regional forecast.
$2.1B market · 2025 base year
View reportDirect to Consumer (DTC) DNA Test Kits Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportDirect-to-consumer DNA Testing Market
Market size, share, segmentation and regional forecast.
$636M market · 2025 base year
View reportOndansetron Hydrochloride Market
Market size, share, segmentation and regional forecast.
$1.0B market · 2025 base year
View reportBuckminsterfullerene Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportAntimicrobial Silicone Masterbatch Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportNettle Root Extract Market
Market size, share, segmentation and regional forecast.
$990M market · 2025 base year
View reportSialic Acid Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportDirect Ray Disinfection Robot Market
Market size, share, segmentation and regional forecast.
$4.0B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy